Kotopoulis, S.; Popa, M.; Mayoral Safont, M.; Murvold, E.; Haugse, R.; Langer, A.; Dimcevski, G.; Lam, C.; Bjånes, T.; Gilja, O.H.;
et al. SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma? Pharmaceutics 2022, 14, 98.
https://doi.org/10.3390/pharmaceutics14010098
AMA Style
Kotopoulis S, Popa M, Mayoral Safont M, Murvold E, Haugse R, Langer A, Dimcevski G, Lam C, Bjånes T, Gilja OH,
et al. SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma? Pharmaceutics. 2022; 14(1):98.
https://doi.org/10.3390/pharmaceutics14010098
Chicago/Turabian Style
Kotopoulis, Spiros, Mihaela Popa, Mireia Mayoral Safont, Elisa Murvold, Ragnhild Haugse, Anika Langer, Georg Dimcevski, Christina Lam, Tormod Bjånes, Odd Helge Gilja,
and et al. 2022. "SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma?" Pharmaceutics 14, no. 1: 98.
https://doi.org/10.3390/pharmaceutics14010098
APA Style
Kotopoulis, S., Popa, M., Mayoral Safont, M., Murvold, E., Haugse, R., Langer, A., Dimcevski, G., Lam, C., Bjånes, T., Gilja, O. H., & Cormack, E. M.
(2022). SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma? Pharmaceutics, 14(1), 98.
https://doi.org/10.3390/pharmaceutics14010098